The Food and Drug Administration provides less stringent oversight of overseas research trials used in deciding whether to approve a drug than those conducted domestically. That was the finding of my recent study, published in the Journal of Clinical Pharmacology. My study highlighted loopholes in the agency’s oversight processes that exploited vulnerable people and led More

The post The FDA’s Lax Oversight of Research in Developing Countries can do Harm to Vulnerable Participants appeared first on CounterPunch.org.

This post was originally published on CounterPunch.org.